Oncology Hematology Care, Inc. - Blue Ash

Cincinnati, OH

Sorting 2 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

Teclistamab

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 2